Stock Track | REMEGEN Soars 8.84% in Pre-Market on Exclusive Licensing Deal with AbbVie

Stock Track

01/13

REMEGEN's stock surged 8.84% in pre-market trading on Tuesday following the announcement of an exclusive licensing agreement with AbbVie for its novel bispecific antibody drug, RC148. The deal grants AbbVie exclusive rights to develop, produce, and commercialize RC148 outside Greater China.

Under the agreement, REMEGEN will receive a $650 million upfront payment and is eligible for up to $4.95 billion in development, regulatory, and commercial milestone payments. Additionally, the company will earn tiered double-digit royalty rates on net sales outside Greater China. This agreement significantly boosts REMEGEN's financial outlook and validates the potential of its drug pipeline.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1105958376"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1105958376\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1105958376?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-13 09:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1105958376","market":"hk","top_or_hot":-1,"title":"Stock Track | REMEGEN Soars 8.84% in Pre-Market on Exclusive Licensing Deal with AbbVie","media":"Stock Track","content":"<p>REMEGEN's stock surged 8.84% in pre-market trading on Tuesday following the announcement of an exclusive licensing agreement with AbbVie for its novel bispecific antibody drug, RC148. The deal grants AbbVie exclusive rights to develop, produce, and commercialize RC148 outside Greater China.</p><p>Under the agreement, REMEGEN will receive a $650 million upfront payment and is eligible for up to $4.95 billion in development, regulatory, and commercial milestone payments. Additionally, the company will earn tiered double-digit royalty rates on net sales outside Greater China. This agreement significantly boosts REMEGEN's financial outlook and validates the potential of its drug pipeline.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | REMEGEN Soars 8.84% in Pre-Market on Exclusive Licensing Deal with AbbVie</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | REMEGEN Soars 8.84% in Pre-Market on Exclusive Licensing Deal with AbbVie\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-01-13 09:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>REMEGEN's stock surged 8.84% in pre-market trading on Tuesday following the announcement of an exclusive licensing agreement with AbbVie for its novel bispecific antibody drug, RC148. The deal grants AbbVie exclusive rights to develop, produce, and commercialize RC148 outside Greater China.</p><p>Under the agreement, REMEGEN will receive a $650 million upfront payment and is eligible for up to $4.95 billion in development, regulatory, and commercial milestone payments. Additionally, the company will earn tiered double-digit royalty rates on net sales outside Greater China. This agreement significantly boosts REMEGEN's financial outlook and validates the potential of its drug pipeline.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09995","symbol_name":"榮昌生物","start_time":0,"source_url":"","article_id":"1105958376","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1105958376","pubTimestamp":1768267855,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"REMEGEN's stock surged 8.84% in pre-market trading on Tuesday following the announcement of an exclusive licensing agreement with AbbVie for its novel bispecific antibody drug, RC148. The deal grants...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09995":"荣昌生物"},"translate_title":"个股追踪|与艾伯维达成独家授权协议REMEGEN盘前大涨8.84%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09995":1},"content_text":"REMEGEN's stock surged 8.84% in pre-market trading on Tuesday following the announcement of an exclusive licensing agreement with AbbVie for its novel bispecific antibody drug, RC148. The deal grants AbbVie exclusive rights to develop, produce, and commercialize RC148 outside Greater China.Under the agreement, REMEGEN will receive a $650 million upfront payment and is eligible for up to $4.95 billion in development, regulatory, and commercial milestone payments. Additionally, the company will earn tiered double-digit royalty rates on net sales outside Greater China. This agreement significantly boosts REMEGEN's financial outlook and validates the potential of its drug pipeline.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}